Vistin Pharma ASA (DE:VP4) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Vistin Pharma ASA reports a stable second quarter in 2024 with a slight increase in revenue to MNOK 106, up from MNOK 107 in the same quarter of the previous year. EBITDA surged by 40% to MNOK 27, attributed to improved product mix and cost control. The company also announced a cash dividend of NOK 0.50 per share distributed in June, with an additional dividend planned for Q4.
For further insights into DE:VP4 stock, check out TipRanks’ Stock Analysis page.